Cervix Tumor-Impedance Measurement System (CT-IMS)
The Cervix Tumor-Impedance Measurement System (CT-IMS) is an innovation designed to address the challenges of cervical cancer screening. By leveraging Electrical Impedance Spectroscopy (EIS), this device provides a non-invasive, rapid, and cost-effective diagnostic solution. Unlike traditional methods such as Pap smears and HPV testing, which are time-consuming, invasive, and reliant on laboratory processing, CT-IMS delivers real-time results directly during clinical assessments. This eliminates delays in diagnosis and treatment, streamlining the decision-making process for healthcare providers.
Special Applications
CT-IMS is particularly beneficial for early detection of cervical abnormalities, high-risk patients with a history of HPV infection, and in resource-limited settings where traditional diagnostic infrastructure is often unavailable. This innovative technology has the potential to transform cervical cancer care, ensuring timely diagnosis and significantly improving patient outcomes.
Technology
The CT-IMS leverages Electrical Impedance Spectroscopy, a cutting-edge technique that measures the electrical properties of biological tissues across a range of frequencies. Each type of tissue exhibits unique impedance characteristics based on its biological properties, including cell density, blood flow, water content, and extracellular matrix composition. These factors vary betwee healthy and abnormal tissues, making impedance an excellent diagnostic parameter.
The CT-IMS probe features four metal electrodes strategically positioned for precise data collection. The system applies a electrical signal within a frequency range of 500 Hz to 500 kHz at an amplitude of 0.4 volts. The impedance magnitude and phase are measured using a hig precision electronic circuit.
These parameters are critical for differentiating between benign and malignant tissues. The system is calibrated against gold-standard pathology results, ensuring high diagnostic accuracy.
Features
The CT-IMS device boasts the following features:
Non-Invasive Testing: Utilizes a contact probe for painless and non-invasive tissue evaluation
during routine examinations.
Real-Time Results: Provides immediate diagnostic insights, reducing the time between screening and treatment initiation.
Cost-Effective: Reduces reliance on laboratory infrastructure, offering a more economical diagnostic alternative.
Achievement
Hospitech Cancer Care Innovations has made significant strides in advancing cancer diagnosis and treatment through its innovative technologies. The development of groundbreaking devices such as the Cervix Tumor-Impedance Measurement System (CT-IMS) showcases the company’s dedication to improving patient care. With multiple patents granted and recognition in esteemed scientific publications, Hospitech continues to set new standards in healthcare innovation. Its contributions have been acknowledged by medical professionals and institutions worldwide, reinforcing its reputation as a leader in the fight against cancer.
Clinical Trial Results
Hospitech Cancer Care Innovations has conducted rigorous clinical trials to validate the effectiveness and reliability of its advanced diagnostic devices. The trials demonstrated exceptional accuracy and precision, confirming the ability of the technologies, including the Cervix Tumor-Impedance Measurement System (CT-IMS), to detect abnormalities early and support timely intervention. The results have been widely recognized in peer-reviewed publications, further establishing the clinical efficacy of these groundbreaking solutions. These findings reinforce Hospitech’s commitment to evidence-based innovation, ensuring healthcare providers and patients receive the highest standard of care.
Related products
Reviews
There are no reviews yet.